Drug Sponsors

Halozyme to expand in San Francisco

Thursday, November 19, 2015

Halozyme Therapeutics, a biotechnology company developing novel oncology and drug-delivery therapies, will be expanding its facilities by opening a satellite office on Gateway Boulevard in South San Francisco. Halozyme is based in San Diego and currently has about 200 employees.

[Read More]

Roche to restructure manufacturing network

Friday, November 13, 2015

Roche, based in Basel, Switzerland, has announced plans to restructure its manufacturing network for small molecules to address current underutilization as a result of its evolving portfolio. A new generation of specialized medicines based on small molecules requires novel manufacturing technologies and will be produced in lower volumes than traditional medicines.

[Read More]

AstraZeneca acquires ZS Pharma

Monday, November 9, 2015

AstraZeneca has entered into a definitive agreement to acquire ZS Pharma, a biopharmaceutical company based in San Mateo, Calif. ZS Pharma uses its proprietary ion-trap technology to develop novel treatments for hyperkalaemia (high potassium levels), a serious condition of elevated potassium in the bloodstream, typically associated with chronic kidney disease (CKD) and chronic heart failure (CHF).

[Read More]

KaloBios to reduce workforce by 61%

Monday, November 9, 2015

KaloBios Pharmaceuticals, based in South San Francisco, Calif., will reduce its workforce as part of a plan to reduce operating costs. The action will reduce the company’s workforce by about 17 employees (or 61%), and will focus the company’s resources on the ongoing development of lenzilumab, also known as KB003, in chronic monomyelocytic leukemia (CMML), while it continues to pursue strategic alternatives for the company.

[Read More]